SHARE
 
David F. Jarrard, MD close
3b_ZEZIJdPU

David F. Jarrard, MD Print Friendly Page

Faculty, University of Wisconsin School of Medicine and Public Health

Dr. Jarrard is board certified by the American Board of Urology and has completed a fellowship in Urologic Oncology. He specializes in all aspects of urologic oncology with an emphasis on prostate cancer diagnosis and treatment. Dr. Jarrard is also involved with surgical treatments for prostate cancer, such as the robotic prostatectomy.

Specialties

Clinics

UW Carbone Cancer Center
(608) 263-4757 | (800) 323-8942 | Map
University Hospital
(608) 263-4757 | (800) 323-8942 | Map

UW School of Medicine and Public Health

Department of Urology

Professional Certifications and Education

Board Certification Urology
Fellowship Urologic Oncology, The Johns Hopkins Hospital, Baltimore, MD
Residency University of Chicago Medical Center, Chicago, IL
Internship University of Chicago Medical Center, Chicago, IL
Medical School University of Virginia School of Medicine, Charlottesville, VA

Medical interpreters are available to help patients communicate with hospital and clinic staff. For more information, please contact interpreter services at (608) 262-9000.
Research

Dr. Jarrard has a joint appointment with the University of Wisconsin Carbone Cancer Center, and his clinical research emphasizes developing new therapies for genitourinary cancers. He has an active basic science laboratory and is funded through the National Institutes of Health to examine genetic and epigenetic alterations in prostate cancer.


PubMed Articles
Posielski NM Richards KA Liou JI Borza T Abel EJ Downs TM Jarrard DF Beta-Adrenergic Antagonists and Cancer Specific Survival in Patients with Advanced Prostate Cancer: A Veterans Administration Cohort Study. Urology . 2021 Feb 12;
[PubMed ID: 33587939]
Luo JH Liu S Tao J Ren BG Luo K Chen ZH Nalesnik M Cieply K Ma T Cheng SY Chen Q Michalopoulos GK Nelson JB Bhargava R Zhang J Ma D Jarrard D Pennathur A Luketich JD DeFranco DB Monga SP Tseng G Yu YP Pten-NOLC1 fusion promotes cancers involving MET and EGFR signalings. Oncogene . 2021 Feb;40(6):1064-1076
[PubMed ID: 33323972]
Jarrard D Filon M Huang W Havighurst T DeShong K Kim K Konety BR Saltzstein D Mukhtar H Wollmer B Suen C House MG Parnes HL Bailey HH A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance. Prostate . 2021 Jan;81(1):41-49
[PubMed ID: 33095939]
Bryce AH Chen YH Liu G Carducci MA Jarrard DM Garcia JA Dreicer R Hussain M Eisenberger MA Plimack ER Vogelzang NJ DiPaola RS Harshman L Sweeney CJ Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial. Eur Urol Oncol . 2020 Dec;3(6):717-724
[PubMed ID: 32807727]
Yang B Damodaran S Khemees TA Filon MJ Schultz A Gawdzik J Etheridge T Malin D Richards KA Cryns VL Jarrard DF Synthetic Lethal Metabolic Targeting of Androgen Deprived Prostate Cancer Cells with Metformin. Mol Cancer Ther . 2020 Sep 17;
[PubMed ID: 32943543]
Bukowy JD Foss H McGarry SD Lowman AK Hurrell SL Iczkowski KA Banerjee A Bobholz SA Barrington A Dayton A Unteriner J Jacobsohn K See WA Nevalainen MT Nencka AS Ethridge T Jarrard DF LaViolette PS Accurate segmentation of prostate cancer histomorphometric features using a weakly supervised convolutional neural network. J Med Imaging (Bellingham) . 2020 Sep;7(5):057501
[PubMed ID: 33062803]
Damaschke NA Gawdzik J Avilla M Yang B Svaren J Roopra A Luo JH Yu YP Keles S Jarrard DF CTCF loss mediates unique DNA hypermethylation landscapes in human cancers. Clin Epigenetics . 2020 Jun 5;12(1):80
[PubMed ID: 32503656]
Hearn JWD Sweeney CJ Almassi N Reichard CA Reddy CA Li H Hobbs B Jarrard DF Chen YH Dreicer R Garcia JA Carducci MA DiPaola RS Sharifi N HSD3B1 Genotype and Clinical Outcomes in Metastatic Castration-Sensitive Prostate Cancer. JAMA Oncol . 2020 Apr 1;6(4):e196496
[PubMed ID: 32053149]
Miller BL Abel EJ Allen G Schumacher JR Jarrard D Downs T Richards KA Trends in epidural anesthesia use at the time of radical cystectomy and its association with perioperative and survival outcomes: a population-based analysis. Am J Clin Exp Urol . 2020;8(1):28-37
[PubMed ID: 32211451]
Shapiro DD Wells SA Best SL Hedican SP Ziemlewicz TJ Lubner MG Hinshaw JL Lee FT Jr Jarrard DF Richards KA Downs TM Allen GO Nakada SY Abel EJ Comparing Outcomes for Patients with Clinical T1b Renal Cell Carcinoma Treated With Either Percutaneous Microwave Ablation or Surgery. Urology . 2020 Jan;135:88-94
[PubMed ID: 31585198]
Yang B Etheridge T McCormick J Schultz A Khemees TA Damaschke N Leverson G Woo K Sonn GA Klein EA Fumo M Huang W Jarrard DF Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies. Clin Epigenetics . 2019 Nov 28;11(1):168
[PubMed ID: 31779677]
Yu J Berthier E Craig A de Groot TE Sparks S Ingram PN Jarrard DF Huang W Beebe DJ Theberge AB Reconfigurable open microfluidics for studying the spatiotemporal dynamics of paracrine signalling. Nat Biomed Eng . 2019 Oct;3(10):830-841
[PubMed ID: 31427781]
Rutkowski DR Wells SA Johnson B Huang W Jarrard DF Lang JM Cho S Roldán-Alzate A Mri-based cancer lesion analysis with 3d printed patient specific prostate cutting guides. Am J Clin Exp Urol . 2019;7(4):215-222
[PubMed ID: 31511828]
Jarrard WE Schultz A Etheridge T Damodaran S Allen GO Jarrard D Yang B Screening of urine identifies PLA2G16 as a field defect methylation biomarker for prostate cancer detection. PLoS One . 2019;14(6):e0218950
[PubMed ID: 31233548]
Damodaran S Lang JM Jarrard DF Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches. J Urol . 2019 May;201(5):876-885
[PubMed ID: 30747897]
Wang JH Sierra P Richards KA Abel EJ Allen GO Downs TM Jarrard DF Impact of bilateral biopsy-detected prostate cancer on an active surveillance population. BMC Urol . 2019 Apr 23;19(1):26
[PubMed ID: 31014300]
Etheridge T Liou JI Downs TM Abel EJ Jarrard DF Richards KA The Impact of Agent Orange Exposure on Prostate Cancer Outcomes. J Urol . 2019 Apr;201(4):742-750
[PubMed ID: 30321553]
Anderson-Carter I Posielski N Liou JI Khemees TA Downs TM Abel EJ Jarrard DF Richards KA The impact of statins in combination with androgen deprivation therapyin patients with advanced prostate cancer: A large observational study. Urol Oncol . 2019 Feb;37(2):130-137
[PubMed ID: 30528885]
Etheridge T Damodaran S Schultz A Richards KA Gawdzik J Yang B Cryns V Jarrard DF Combination therapy with androgen deprivation for hormone sensitive prostate cancer: A new frontier. Asian J Urol . 2019 Jan;6(1):57-64
[PubMed ID: 30775249]
Richards KA Liou JI Cryns VL Downs TM Abel EJ Jarrard DF Metformin Use is Associated with Improved Survival for Patients with Advanced Prostate Cancer on Androgen Deprivation Therapy. J Urol . 2018 Dec;200(6):1256-1263
[PubMed ID: 29940252]